Exploring the Use of Induced Pluripotent Stem Cells in Healing
Stem cell therapy has been gaining much attention in recent years as a potential therapy for various medical conditions. One type of stem cell that is currently being used in therapeutic applications is induced pluripotent stem cells (iPSCs). These cells are generated from adult cells and can be reprogrammed to behave like embryonic stem cells, […]
Stem Cell Therapy Shows Promise for Age-Related Macular Degeneration
A recent study has demonstrated the potential of stem cell therapy as a treatment for age-related macular degeneration (AMD), a leading cause of vision loss in older adults. Researchers from the RIKEN Center for Biosystems Dynamics Research have developed a new method of transforming stem cells into retinal cells, which has shown promising results in […]
Unlocking the Potential of Stem Cell Therapy in Treating Parkinson’s Disease
Stem cell therapy is an emerging and promising treatment method that has been linked to various diseases, such as Parkinson’s Disease. Stem cells are unique in their ability to develop into specialized cells, tissues, and organs, which allows them to replace cells that have been damaged or lost due to disease. In the context of […]
StemBioSys Announces Launch of NeuroMatrix™, a Technological Leap Forward in Laboratory Production of Functionally Mature Human Neural Cell Types
SAN ANTONIO, Feb. 13, 2023 /PRNewswire/ — StemBioSys, Inc. (StemBioSys) announced today the launch of NeuroMatrix™, an astrocyte-derived extracellular matrix that enables the culture of human induced pluripotent stem cell (hiPSC) derived and primary neural cell types. StemBioSys designed NeuroMatrix™ to expand the use of iPSC-derived neurons in drug discovery and toxicity testing. “NeuroMatrix™ represents a breakthrough in hiPSC-derived neuronal development […]
The Different Types of Stem Cells and How They are Used in Therapy
If you’re dealing with a health condition and looking for ways to get relief, you may have heard of stem cell therapy. But what are stem cells, and how can they help? Let’s take a look at the different types of stem cells and how they can be used in therapy. Mesenchymal Stem Cells (MSCs) […]
FUJIFILM Cellular Dynamics Announces License Agreement with Novo Nordisk for the Development of iPSC-Derived Cell Therapies
MADISON, Wis., Jan. 05, 2023 (GLOBE NEWSWIRE) — FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC), announced today that it has entered an agreement to grant global healthcare company Novo Nordisk A/S a non-exclusive right to use FUJIFILM Cellular Dynamics’ iPSC platform for the development and […]
Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
PHILADELPHIA, Jan. 04, 2023 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 9:45 AM PT. A live webcast of […]
Aspen Neuroscience Inks $40 Million Debt Deal with Silicon Valley Bank
SAN DIEGO, Dec. 21, 2022 /PRNewswire/ — Aspen Neuroscience, Inc., a private biotechnology company developing autologous cell therapies including the first iPSC-derived autologous neuron replacement treatment for Parkinson’s disease (PD), has signed a $40 million credit facility with Silicon Valley Bank (SVB). Deal terms were not disclosed. “We are pleased to work with Silicon Valley Bank. As a leader […]
Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting
SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, presented preclinical data of several novel strategies designed to enable administration of off-the-shelf cell-based cancer immunotherapies without conditioning chemotherapy at the 64th American Society of Hematology […]
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022
BRISBANE, CALIFORNIA, Dec. 12, 2022 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (NASDAQ: GTBP) today announced the presentation of new preclinical data at the American Society of Hematology’s 64th Annual Meeting (ASH 2022). The presentation highlights the potential of a novel dual antigen targeting approach for the treatment of acute myeloid leukemia (AML) by combining GT […]